PRMT5 and cervical carcinoma: Previous studies have shown that PRMT5, a type II PRMT, is highly expressed in cervical cancer, and arginine methyltransferase inhibitor 1 (AMI-1) can inhibit solid tumors of cervical cancer by targeting PRMT5 (93).